Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
33,56 USD | +3,36 % | +3,55 % | +55,95 % |
26/03 | SPYRE THERAPEUTICS, INC. : Recibe una recomendación de compra del Stifel Nicolaus | ZM |
01/03 | SPYRE THERAPEUTICS, INC. : Wells Fargo Securities Cambia su recomendación a compra | ZM |
Resumen de negocios
Número de empleados: 30
Ventas por actividad
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Human Enzyme Therapeutics
100,0
%
| 2 | 100,0 % | 1 | 100,0 % | -61,96 % |
Ventas por región
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 2 | 100,0 % | 1 | 100,0 % | -61,96 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Cameron Turtle
CEO | Chief Executive Officer | 34 | 22/06/23 |
Scott Burrows
DFI | Director of Finance/CFO | 47 | 01/09/23 |
Brian Connolly
CTO | Chief Tech/Sci/R&D Officer | - | 27/11 |
Chief Tech/Sci/R&D Officer | 56 | 01/02/14 | |
Mira Huyghe
PRN | Corporate Officer/Principal | - | 27/11 |
Deanna Nguyen
PRN | Corporate Officer/Principal | - | 27/11 |
Joshua Friedman
PRN | Corporate Officer/Principal | - | 27/11 |
General Counsel | 41 | 05/09/23 | |
Paul Fehlner
PRN | Corporate Officer/Principal | 61 | 27/11 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Tomas Kiselak
BRD | Director/Board Member | 38 | 22/06/23 |
Russell Cox
CHM | Chairman | 60 | 01/06/15 |
Jeffrey Albers
BRD | Director/Board Member | 52 | 27/11 |
Peter Harwin
BRD | Director/Board Member | 38 | 22/06/23 |
Laurie Stelzer
BRD | Director/Board Member | 56 | 27/11 |
Director/Board Member | 34 | 22/06/23 | |
Mark Mckenna
BRD | Director/Board Member | 48 | 01/02 |
Cameron Turtle
CEO | Chief Executive Officer | 34 | 22/06/23 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 0 | 150 000 | 0 | 0 | 87,42 % |
Acción B | 1 | 36 599 786 | 31 994 842 ( 87,42 %) | 0 | |
Acción C | 0 | 437 037 | 0 | 0 |
Información de la empresa
Spyre Therapeutics, Inc.
Building 17 221 Crescent Street
02453, Waltham
+617 651 5940
http://www.aeglea.comSector
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+55,95 % | 1228,46 M | |
-2,31 % | 103 mil M | |
+0,56 % | 95,28 mil M | |
+1,69 % | 22,15 mil M | |
-17,37 % | 21,02 mil M | |
-9,30 % | 18,15 mil M | |
-41,01 % | 16,74 mil M | |
-14,85 % | 16,05 mil M | |
+3,21 % | 13,68 mil M | |
+33,54 % | 12,17 mil M |
- Bolsa de valores
- Acciones
- Acción SYRE
- Empresa Spyre Therapeutics, Inc.